Overall survival (OS)
The CR rate after initial treatment of all 298 GTN patients approached
88.4% and the 5-year OS rate of all 298 GTN patients was 98.7%, with a
median follow-up time of six years (range: 62–82 months; IQR: 20
months) (Figures 2, 3). The CR rate after initial treatment in
ultra-high-risk patients approached 11.1% and the 5-year OS rate was
77.8% (n=18). The CR rate after initial treatment in ultra-high-risk
patients with liver or brain metastases approached 0% and the 5-year OS
rate was 81.8% (n=11).
Survival time was significantly shorter among patients with than in
those without brain and liver metastases (P <0.01,
log-rank test; Figures 2, 3).